The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

Biohaven has a 12 month low of $26.80 and ... The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric ...

Biohaven Ltd. (NYSE:BHVN – Get Free Report ... The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric ...

After hours: February 19 at 5:10:43 PM EST ...

This stock can be held in an Investment ISA and an Investment Account ...